Search

Your search keyword '"Soo, R A"' showing total 330 results
Start Over Author "Soo, R A"
330 results on '"Soo, R A"'

4. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Author

Addeo, A., Albiges, L., Ascierto, P.A., Banerjee, S., Barlesi, F., Caldas, C., Cardoso, F., Cervantes, A., Chaberny, I.F., Cherny, N.I., Choueiri, T.K., Chua, M.L.K., Criscitiello, C., Curigliano, G., de Azambuja, E., De Ruysscher, D., de Vries, E., Dent, R., Douillard, J.Y., D’Ugo, D., Dziadziuszko, R., Faivre-Finn, C., Felip, E., Garassino, M., Garrido, P., Girard, N., Glynne-Jones, R., Golfinopoulos, V., Haanen, J., Hamilton, E., Jänne, P.A., Jordan, K., Kanesvaran, R., Kim, S.B., Liebert, U.G., Lordick, F., Machiels, J.P., Michielin, O., Mok, T.S.K., Morgan, G., Obermannova, R., Park, K., Passaro, A., Pentheroudakis, G., Peters, S., Reck, M., Salazar Soler, R., Scotté, F., Senan, S., Sessa, C., Smyth, E., Soo, R., Soria, J.C., Spicer, J., Strasser, F., Tabernero, J., Tan, D.S.W., Trapani, D., Van Cutsem, E., van Halteren, H., van Schil, P.E., Veronesi, G., Yang, J., and Garassino, M.C.

Published
2020
Full Text
View/download PDF

9. Reticent Students in the ESL Classrooms

Author

Soo, R. S. and Goh, H. S.

Abstract

Reticence has always been regarded as a problematic phenomenon among students in the ESL classrooms. Many instructors have expressed their frustrations to decode the reticent behaviour and work out suitable strategies to help students with such behaviour. Whenever such students do not engage in the classroom discourse, they are usually regarded as not having the desire to learn or lacking in cooperation. These explanations seem simplistic, bias and stereotypical. Based on a larger project on students' reticent behaviour, this study investigated the extent in which tertiary students majoring in English experience reticence in the classrooms, and examined the underlying factors of reticence. Data were obtained from 78 students utilizing the Reticence Scale-12 (RS-12) which measures the level of reticence along six dimensions: anxiety, knowledge, timing, organization, skills and memory. The findings reveal that reticent level is high among the students, and their major problems lie in affective-control and delivery.

Published
2013

11. A toolkit for DNA assembly, genome engineering and multicolor imaging for C. elegans

Author

Bryan Sands, Nikolay Burnaevskiy, Soo R. Yun, Matthew M. Crane, Matt Kaeberlein, and Alexander Mendenhall

Subjects
Medicine
Abstract

One way scientists can observe and quantify processes in living cells is to engineer the genomes of animals to express multiple fluorescent proteins and then quantify those signals by various imaging techniques. To allow our laboratories to confidently quantify mixed (overlapping) fluorescent signals for our studies in the basic biology of gene expression and aging in C. elegans, we developed a comprehensive toolkit for C. elegans that we describe here. The Toolkit consists of two components: 1) a series of vectors for DNA assembly by homologous recombination (HR) in the yeast, Saccharomyces cerevisiae, and 2) a set of ten worm strains that each express a single, spectrally distinct fluorescent protein, under control of either the daf-21 or eft-3 promoters. We measured the in vivo emission spectrum (3 nm resolution) for each fluorescent protein in live C. elegans and showed that we can use those pure spectra to unmix overlapping fluorescent signals in spectral images of intestine cells. Seven of ten fluorescent proteins had signals that appeared to be localized in vesicular/elliptical foci or tubules in the hypodermis. We conducted fluorescence recovery after photobleaching (FRAP) experiments and showed that these structures have recovery kinetics more consistent with freely diffusing protein than aggregates (Q35:YFP). This toolkit will allow researchers to quickly and efficiently generate mutlti-fragment DNA assemblies for genome editing in C. elegans. Additionally, the transgenic C. elegans and the measured emission spectra should serve as a resource for scientists seeking to perform, or test their ability to perform, multidimensional (multi-color) imaging experiments.

Published
2018
Full Text
View/download PDF

12. PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT

Author

OHara, R., primary, Kin Liam, C., additional, Rozila Ahmad, A., additional, Hsia, T.-C., additional, Zhou, J., additional, Kim, D.-W., additional, Andrew Soo, R., additional, Cheng, Y., additional, Lu, S., additional, Won Shin, S., additional, Chih-Hsin Yang, J., additional, Zhang, Y., additional, Zhao, J., additional, Bruns, R., additional, Johne, A., additional, and Wu, Y.-L., additional

Published
2023
Full Text
View/download PDF

13. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis

Author

Dafni, U., Soo, R. A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J-Y, De Castro, J., Coate, L., Fruh, M., Hashemi, S. M. S., Nadal, E., Carcereny, E., Sala, M. A., Bernabe, R., Provencio, M., Cuffe, S., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R. A., [Dafni, U.] Natl & Kapodistrian Univ Athens, Athens, Greece, [Dafni, U.] Frontier Sci Fdn Hellas, Athens, Greece, [Tsourti, Z.] Frontier Sci Fdn Hellas, Athens, Greece, [Zygoura, P.] Frontier Sci Fdn Hellas, Athens, Greece, [Vervita, K.] Frontier Sci Fdn Hellas, Athens, Greece, [Soo, R. A.] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore, [Peters, S.] Ctr Hosp Univ Vaudois CHUV, Lausanne, Switzerland, [Peters, S.] Univ Lausanne, Lausanne, Switzerland, [Han, J-Y] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea, [De Castro, J.] Hosp Univ La Paz, Med Oncol Dept, Madrid, Spain, [De Castro, J.] Spanish Lung Canc Grp SLCG, Barcelona, Spain, [Nadal, E.] Spanish Lung Canc Grp SLCG, Barcelona, Spain, [Carcereny, E.] Spanish Lung Canc Grp SLCG, Barcelona, Spain, [Sala, M. A.] Spanish Lung Canc Grp SLCG, Barcelona, Spain, [Bernabe, R.] Spanish Lung Canc Grp SLCG, Barcelona, Spain, [Provencio, M.] Spanish Lung Canc Grp SLCG, Barcelona, Spain, [Coate, L.] Midwestern Canc Ctr, Limerick, Ireland, [Coate, L.] Univ Hosp Limerick, Limerick, Ireland, [Coate, L.] Canc Trials Ireland, Innovat House, Dublin, Ireland, [Cuffe, S.] Canc Trials Ireland, Innovat House, Dublin, Ireland, [Fruh, M.] Cantonal Hosp St Gallen, Oncol & Hematol, St Gallen, Switzerland, [Fruh, M.] Inselspital Bern, Dept Oncol, Bern, Switzerland, [Fruh, M.] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland, [Hashemi, S. M. S.] Vrije Univ Amsterdam Med Ctr, Dept Pulm Dis, Amsterdam UMC, Amsterdam, Netherlands, [Nadal, E.] ICO LHosp, Med Oncol Dept, Barcelona, Spain, [Carcereny, E.] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol Badalona, B ARGO Grp, Med Oncol Dept, Badalona, Spain, [Sala, M. A.] Hosp Univ Basurto, Med Oncol Dept, Bilbao, Spain, [Bernabe, R.] Hosp Virgen Rocio, Med Oncol Dept, Seville, Spain, [Provencio, M.] Hosp Puerta Hierro, Majadahonda Med Oncol Serv, Madrid, Spain, [Cuffe, S.] St James Hosp, Dept Med Oncol, Dublin, Ireland, [Roschitzki-Voser, H.] ETOP IBCSG Partners Fdn, Coordinating Off, Effingerstr 33, CH-3008 Bern, Switzerland, [Ruepp, B.] ETOP IBCSG Partners Fdn, Coordinating Off, Effingerstr 33, CH-3008 Bern, Switzerland, [Stahel, R. A.] ETOP IBCSG Partners Fdn, Coordinating Off, Effingerstr 33, CH-3008 Bern, Switzerland, [Rosell, R.] Germans Trias & Pujol Res Inst IGTP, Badalona, Spain, [Rosell, R.] Catalan Inst Oncol ICO, Honorary Consultant, Barcelona, Spain, AstraZeneca, and F. Hoffmann-La Roche

Subjects
Plus bevacizumab, Erlotinib, Survival, EGFR-TKI, Cell lung-cancer, NSCLC, Multicenter, Monotherapy, EGFR mutations, randomised controlled trial, Mutations, Osimertinib, smoking status
Abstract

Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in patients with a smoking history and prompted us to do this study.Methods: A systematic review and meta-analysis to evaluate the differential effect of smoking status on the benefit of adding an angiogenesis inhibitor to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor therapy was carried out. All relevant randomized controlled trials appearing in main oncology congresses or in PubMed as of 1 November 2021 were used according to the Preferred Reporting Items for Systematic Review and Meta-Analyses statement. Primarily PFS according to smoking status, and secondarily overall survival (OS) were of interest. Pooled and interaction hazard ratios (HRs) were estimated by fixed or random effects models, depending on the detected degree of heterogeneity. Bias was assessed using the revised Cochrane tool for randomized controlled trials (RoB 2).Results: Information by smoking was available for 1291 patients for PFS (seven studies) and 678 patients for OS (four studies). The risk of bias was low for all studies. Combination treatment significantly prolonged PFS for smokers [n =502, HR = 0.55, 95% confidence interval (CI): 0.44-0.69] but not for nonsmokers (n = 789, HR = 0.92, 95% CI: 0.66-1.27; treatment-by-smoking interaction P= 0.02). Similarly, a significant OS benefit was found for smokers (n =271, HR 0.66, 95% CI: 0.47-0.93) but not for nonsmokers (n = 407, HR = 1.07, 95% CI: 0.82-1.42; treatment-by-smoking interaction P= 0.03).Conclusion: In advanced EGFR-non-small-cell lung cancer patients, the addition of an angiogenesis inhibitor to EGFR-tyrosine kinase inhibitor therapy provides a statistically significant PFS and OS benefit in smokers, but not in nonsmokers. The biological basis for this observation should be pursued and could determine whether this might be due to a specific co-mutational pattern produced by tobacco exposure.

Published
2022

14. LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

Author

Cho, B.C., primary, Ahn, M-J., additional, Kang, J.H., additional, Soo, R., additional, Baisamut (Reungwetwattana), T., additional, Yang, J.C-H., additional, Cicin, I., additional, Kim, D-W., additional, Wu, Y-L., additional, Lu, S., additional, Lee, K., additional, Pang, Y-K., additional, Zimina, A., additional, Fong, C.H., additional, Poddubskaya, E., additional, Kim, Y., additional, An, T., additional, Lee, H., additional, Byun, H., additional, and Zaric, B., additional

Published
2022
Full Text
View/download PDF

15. 405P Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019

Author

Soo, R., primary, Mery, L., additional, Bardot, A., additional, Kanesvaran, R., additional, Keong, T., additional, Pongnikorn, D., additional, Prasongsook, N., additional, Hutajulu, S., additional, Irawan, C., additional, Ab Manan, A., additional, Thiagarajan, M., additional, Sripan, P., additional, Peters, S., additional, Storm, H., additional, Bray, F., additional, and Stahel, R., additional

Published
2022
Full Text
View/download PDF

20. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis

Author

Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J-Y, De Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, R A, Pulmonary medicine, and CCA - Cancer Treatment and quality of life

Subjects
ErbB Receptors, Cancer Research, Lung Neoplasms, Oncology, Carcinoma, Non-Small-Cell Lung, Smoking, Humans, 610 Medicine & health, Angiogenesis Inhibitors, Antineoplastic Agents, Protein Kinase Inhibitors
Abstract

BACKGROUND The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in patients with a smoking history and prompted us to do this study. METHODS A systematic review and meta-analysis to evaluate the differential effect of smoking status on the benefit of adding an angiogenesis inhibitor to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor therapy was carried out. All relevant randomized controlled trials appearing in main oncology congresses or in PubMed as of 1 November 2021 were used according to the Preferred Reporting Items for Systematic Review and Meta-Analyses statement. Primarily PFS according to smoking status, and secondarily overall survival (OS) were of interest. Pooled and interaction hazard ratios (HRs) were estimated by fixed or random effects models, depending on the detected degree of heterogeneity. Bias was assessed using the revised Cochrane tool for randomized controlled trials (RoB 2). RESULTS Information by smoking was available for 1291 patients for PFS (seven studies) and 678 patients for OS (four studies). The risk of bias was low for all studies. Combination treatment significantly prolonged PFS for smokers [n = 502, HR = 0.55, 95% confidence interval (CI): 0.44-0.69] but not for nonsmokers (n = 789, HR = 0.92, 95% CI: 0.66-1.27; treatment-by-smoking interaction P = 0.02). Similarly, a significant OS benefit was found for smokers (n = 271, HR = 0.66, 95% CI: 0.47-0.93) but not for nonsmokers (n = 407, HR = 1.07, 95% CI: 0.82-1.42; treatment-by-smoking interaction P = 0.03). CONCLUSION In advanced EGFR-non-small-cell lung cancer patients, the addition of an angiogenesis inhibitor to EGFR-tyrosine kinase inhibitor therapy provides a statistically significant PFS and OS benefit in smokers, but not in non-smokers. The biological basis for this observation should be pursued and could determine whether this might be due to a specific co-mutational pattern produced by tobacco exposure.

Published
2022

23. P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)

Author

Liam, C.K., primary, Rozila Ahmad, A., additional, Hsia, T., additional, Li, J.Y., additional, Le, X., additional, Heymach, J., additional, Yang, J.C., additional, Soo, R., additional, Zhang, Y., additional, Kim, S., additional, Shin, S.W., additional, Johne, A., additional, Karachaliou, N., additional, Bruns, R., additional, Ellers-Lenz, B., additional, and Wu, Y., additional

Published
2021
Full Text
View/download PDF

25. OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers

Author

Smeltzer, M., primary, Bunn, B., additional, Choi, Y.S., additional, Coate, L., additional, Corona-Cruz, J., additional, Drilon, A., additional, Duma, N., additional, Edelman, M., additional, Fidler, M.J., additional, Gadgeel, S., additional, Goto, Y., additional, Herbst, R., additional, Hesdorffer, M., additional, Higgins, K., additional, Labdi, B., additional, Leal, T., additional, Liu, S., additional, Mazotti, J., additional, Novello, S., additional, Patel, S., additional, Popat, S., additional, Ramirez, R., additional, Reckamp, K., additional, Reguart, N., additional, Soo, R., additional, Tan, A., additional, Wolf, J., additional, Yano, S., additional, Stiles, B., additional, and Baird, A., additional

Published
2021
Full Text
View/download PDF

27. 1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)

Author

Solomon, B.J., primary, Martini, J-F., additional, Bearz, A., additional, Tan, E.H., additional, Soo, R., additional, Besse, B., additional, Bauer, T.M., additional, Shepard, D., additional, Toffalorio, F., additional, Abbattista, A., additional, Felip, E., additional, Shaw, A.T., additional, Viteri, S., additional, Camidge, D.R., additional, Seto, T., additional, and Ou, S-H.I., additional

Published
2021
Full Text
View/download PDF

28. 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

Author

Lim, J.S., primary, Sundar, R., additional, Wong, A., additional, Yong, W-P., additional, Soo, R., additional, Chee, C.E., additional, Lee, S.C., additional, Goh, B.C., additional, Dent, R., additional, Jeraj, S. d/o Nathan, additional, Kwok, L., additional, Schiavon, G., additional, Kaliaperumal, N., additional, Foxley, A., additional, Connolly, J.E., additional, and Tan, D.S., additional

Published
2021
Full Text
View/download PDF

30. 1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN

Author

Zhou, Q., primary, Kim, H.R., additional, Soo, R., additional, Chang, G-C., additional, Chiu, C-H., additional, Hayashi, H., additional, Kim, S-W., additional, Teraoka, S., additional, Goto, Y., additional, Zhou, J., additional, Lee, V.H.F., additional, Han, B., additional, Ho, J.C.M., additional, Kim, D-W., additional, Lin, C-C., additional, Lu, S., additional, Polli, A., additional, Calella, A.M., additional, Mok, T.S.K., additional, and Wu, Y-L., additional

Published
2021
Full Text
View/download PDF

31. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer

Author

Low, JL, Huang, Y, Sooi, K, Ang, Y, Chan, ZY, Spencer, K, Devaprasath Jeyasekharan, A, Sundar, R, Goh, BC, Soo, R, and Yong, WP

Abstract

A dose of 200 mg 3-weekly of pembrolizumab was approved by the Food and Drug Administration (FDA) as treatment for advanced non-small cell lung cancer (NSCLC) without oncogenic drivers. This is despite evidence showing no difference in efficacy with 2 mg/kg. Our study aimed to assess the efficacy of a lower fixed dose of 100 mg, which is closer to 2 mg/kg weight-based dose in an average-sized Asian patient. All patients receiving pembrolizumab for advanced NSCLC from January 2016 to March 2020 in National University Hospital, Singapore, were included in this retrospective observational study. The effect of pembrolizumab 100 mg (Pem100) vs 200 mg (Pem200) upon survival outcomes, toxicity and cost were examined. One hundred fourteen patients received pembrolizumab. Sixty-five (57%) and 49 (43%) received Pem100 and Pem200, respectively. There was no difference in progression-free survival (PFS) and overall survival (OS) between Pem100 vs Pem200 as a single agent (PFS: 6.8 vs 4.2 months, hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.36-1.46, P = .36; 9 month OS: 58% vs 63%, HR 1.08, 95% CI 0.48-2.41, P = .86) and when combined with chemotherapy (9-month PFS: 60% vs 50%, HR0.84, 95% CI 0.34-2.08, P = .71; 9-month OS: 85% vs 58%, HR 0.27, 95% CI 0.062-1.20, P = .09). No significant difference in response rate or ≥G3 immune-related toxicities between Pem100 and Pem200 was observed. A cost minimisation analysis evaluating the degree of cost savings related to drug costs estimated a within study cost saving of SGD4,290,912 and cost saving per patient of SGD39,942 in the Pem100 group. A 100 mg of pembrolizumab appears to be effective with reduction in cost. A randomised trial should be done to investigate a lower dose of pembrolizumab.

Published
2021

32. Abstract 868: Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization

Author

Guilherme Harada, Christina J. Falcon, Fernando C. Santini, Jason C. Chang, Soo R. Yang, Maria E. Arcila, Natasha Rekhtman, and Alexander Drilon

Subjects
Cancer Research, Oncology
Abstract

Background: Splicing factor mutations can drive oncogenesis in different cancer types. More importantly, strategies to target splicing-dependent cancers have been developed, including PRMT5 inhibition which regulates alternative splicing and targets posttranslational modification; PRMT5 inhibitors are in ongoing phase I clinical trials. The characterization of splicing alterations in non-small cell lung cancer (NSCLC) has not been extensively studied and represents an unmet need. Methods: Based on previously known genes associated with splicing alterations, genomic and clinicopathologic data from NSCLC patients with hotspot or loss of function mutations identified by next-generation sequencing in the splicing factors SF3B1, SRSF2, U2AF1, ZRSR2, RBM10, and FUBP1 were explored. Results: Among 626 NSCLC patients with at least one splicing mutation, 85% (529/626) also harbored a co-occurring oncogenic driver, such as alterations involving KRAS (60%; 319/529), EGFR (25%;132/529), MET (5%; 27/529), BRAF(4%; 24/529), and ERBB2 (3%; 17/529). After excluding patients with concurrent drivers, 97 splicing-factor-mutant NSCLCs were identified, with 80 (82%) adenocarcinomas and 6 (6%) squamous cell carcinomas. The median age was 71 years (43-89). Forty-nine patients (51%) were female. Sixty patients (62%) were diagnosed with stage I-III disease. Eleven (11%) were never smokers, while 86 (89%) were former/current smokers, with a median of pack years of 30. The median tumor mutational burden was 7.9 mut/Mb (0.9-90.4). Regarding splicing factor mutations, sixty-two patients (64%) had nonsense or splice-site RBM10 mutations, 17 (17%) had missense hotspot SF3B1 mutations, 16 (16%) had hotspot missense U2AF1 mutations, and 7 (7%) had nonsense, splice-site, or hotspot missense FUBP1 mutation. No patients with ZRSR2 or SRSF2 were identified. Only three patients presented concurrent splicing mutations: one with two SF3B1 mutations; one with RBM10 and SF3B1 mutations; and one with U2AF1 and SF3B1 mutations. Conclusion: Most patients with splicing factor mutant NSCLCs are smokers whose cancers commonly harbor RBM10 mutations and higher TMB compared to other driver-positive cancers. The characterization of this profile is key to identifying appropriate patients for ongoing targeted therapy trials for this population. Citation Format: Guilherme Harada, Christina J. Falcon, Fernando C. Santini, Jason C. Chang, Soo R. Yang, Maria E. Arcila, Natasha Rekhtman, Alexander Drilon. Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 868.

Published
2022

34. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Author

Soo, R., Han, J-Y., Dimopoulou, G., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabe, R., Coate, L., Provencio, M., Campelo, R. Garcia, Cuffe, S., Hashemi, S., Früh, M., Ruepp, B., Roschitzki-Voser, H., Stahel, R., and Peters, S.

Published
2021
Full Text
View/download PDF

36. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Author

Wong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., Soong, R., Yee, M. Q., Chin, T. M., Cordero, M. T., Asuncion, B. R., Pang, B., Pervaiz, S., Hirpara, J. L., Sinha, A., Xu, W. W., Yuasa, M., Tsunoda, T., Motoyama, M., Yamauchi, T., and Goh, B. C.

Published
2015
Full Text
View/download PDF

37. 40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies

Author

Ho, J.S., primary, Heong, V., additional, Yong, W.P., additional, Soo, R., additional, Chee, C.E., additional, Wong, A., additional, Thian, Y.L., additional, Sundar, R., additional, Gopinathan, A., additional, Lee, S.C., additional, Goh, B.C., additional, Xu, H., additional, and Tan, D.S., additional

Published
2021
Full Text
View/download PDF

43. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Author

Curigliano, G., primary, Banerjee, S., additional, Cervantes, A., additional, Garassino, M.C., additional, Garrido, P., additional, Girard, N., additional, Haanen, J., additional, Jordan, K., additional, Lordick, F., additional, Machiels, J.P., additional, Michielin, O., additional, Peters, S., additional, Tabernero, J., additional, Douillard, J.Y., additional, Pentheroudakis, G., additional, Addeo, A., additional, Albiges, L., additional, Ascierto, P.A., additional, Barlesi, F., additional, Caldas, C., additional, Cardoso, F., additional, Chaberny, I.F., additional, Cherny, N.I., additional, Choueiri, T.K., additional, Chua, M.L.K., additional, Criscitiello, C., additional, Curigliano, G., additional, de Azambuja, E., additional, De Ruysscher, D., additional, de Vries, E., additional, Dent, R., additional, D’Ugo, D., additional, Dziadziuszko, R., additional, Faivre-Finn, C., additional, Felip, E., additional, Garassino, M., additional, Glynne-Jones, R., additional, Golfinopoulos, V., additional, Hamilton, E., additional, Jänne, P.A., additional, Kanesvaran, R., additional, Kim, S.B., additional, Liebert, U.G., additional, Mok, T.S.K., additional, Morgan, G., additional, Obermannova, R., additional, Park, K., additional, Passaro, A., additional, Reck, M., additional, Salazar Soler, R., additional, Scotté, F., additional, Senan, S., additional, Sessa, C., additional, Smyth, E., additional, Soo, R., additional, Soria, J.C., additional, Spicer, J., additional, Strasser, F., additional, Tan, D.S.W., additional, Trapani, D., additional, Van Cutsem, E., additional, van Halteren, H., additional, van Schil, P.E., additional, Veronesi, G., additional, and Yang, J., additional

Published
2020
Full Text
View/download PDF

45. 1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

Author

Felip, E., primary, Minotti, V., additional, Soo, R., additional, Wolf, J., additional, Solomon, B., additional, Tan, D.S.W., additional, Ardizzoni, A., additional, Lee, D.H., additional, Sequist, L.V., additional, Barlesi, F., additional, Paz-Ares, L., additional, Rodriguez-Abreu, D., additional, Campelo, M.R. Garcia, additional, Sprauten, M., additional, O’Sullivan Djentuh, L., additional, Belli, R., additional, Glaser, S., additional, Zou, M., additional, Giovannini, M., additional, and Yang, J.C-H., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results